A-Alpha Bio is a biotechnology company using synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. We pursue our mission of improving human health through an internal therapeutics pipeline and by partnering with industry-leading pharmaceutical and technology companies.

Current approaches for measuring protein-protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. Our proprietary experimental platform, AlphaSeq, generates high-resolution data to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, and generate massive protein-protein interaction datasets to map the protein binding landscape. Our AlphaBind platform then leverages these data to train predictive machine learning models to further accelerate the discovery and optimization of high-impact therapeutics.

A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology and is based in Seattle, Washington.

National Science Foundation

U.S. Department of Defense

Bill & Melinda Gates Foundation

AME Cloud Ventures

Washington Research Foundation

Sahsen Ventures

OS Fund

Madrona

Boom Capital

Perceptive Advisors

Lux Capital

Farvatn Venture

Breakout Ventures

A-Alpha Bio

We are excited to participate in the 2nd Annual Molecular Glue Drug Development Summit in Boston this week! During the summit, we will share our latest work on applying AlphaSeq and AlphaBind for molecular glue discovery. 

In his talk, A-Alpha Bio Co-Founder and CTO Randolph Lopez will showcase how we use our platforms to improve the efficiency of identifying latent E3 ligase-target interactions using high-throughput experiments and machine learning. 

A-Alpha Bio Senior Scientist Arpita Sen will present a poster on how our platforms enable a high-throughput approach to discover novel glueable ligase-target pairs. 

If you’re attending, catch Randolph’s talk and stop by Arpita’s poster on February 1st to learn more. 
 
#molecularglues #biotech

"I've leaned into my strengths as a multidisciplinary expert, guiding the company’s growth and expanding our platform across various therapeutic areas and applications."

A-Alpha Bio Co-Founder and CTO, Randolph Lopez, talks about his journey from growing up in Venezuela to harnessing synthetic biology and machine learning to improve human health. 

Thanks to JDI (Jones-Dilworth, Inc.) for featuring Randolph's story in The Superposition!

https://lnkd.in/gMj45saz

Now hiring for a Senior Scientist on our Immunobiology team! Come join A-Alpha Bio on our quest to improve human health!
https://lnkd.in/gNQuCP6S

A-Alpha Bio is excited to participate in the 23rd Annual PepTalk Conference in San Diego, where we will showcase our latest work in antibody design and optimization. In his talk, A-Alpha Bio Co-Founder and CTO, Randolph Lopez, will delve into the applications of our AlphaSeq and AlphaBind platforms in the discovery and optimization of rare, cross-reactive antibodies. If you're attending PepTalk, please tune in this Friday, January 19th, to learn more.

#peptalk  #biotech

We have another new open position here at A-Alpha! Check out our posting for a Scientist I on our Protein Science team.
https://lnkd.in/gaKWsSFq

We are excited to share the results of our recent collaboration with Google and Lumen Bioscience! 

With funding from the Bill & Melinda Gates Foundation, we’ve used AlphaSeq and machine learning (ML) to generate highly diverse single-domain antibodies that bind and neutralize SARS-CoV-2 variants with broad cross-reactivity. 

Through multiple iterations of AlphaSeq data generation, ML model training, and antibody design, we generated thousands of antibody variants showing enhanced binding against diverse SARS-CoV-2 strains. The most promising antibody candidates were expressed recombinantly and evaluated with biolayer interferometry and viral neutralization assays, demonstrating up to 100-fold improvement in binding and neutralization compared to the parental antibody.

The end result is twofold: (1) therapeutic variants showing potent neutralization of diverse viral variants, and (2) an ML approach that can predict binding across vast regions of sequence space and may help future-proof therapeutics against rapidly evolving pathogens. 

Check out the preprint here: https://lnkd.in/gH7GqJJm

We have yet another new open position here at A-Alpha! Check out our posting for a Senior Research Associate on our Platform R&D team.
https://lnkd.in/eCbMaS9s

A-Alpha is now hiring for an Associate Scientist on our Immunobiology team!
https://lnkd.in/gc9MSj_G

A-Alpha is newly hiring for a Senior Scientist, Computational Protein Engineering! Come join our fantastic Data Science/ML team and work with the amazingly smart, talented, and driven individuals we have here. https://lnkd.in/gpTSjyNT

A-Alpha is hiring for an entry-level Research Assistant I on our Technical Operations team! Check out our posting - this is an amazing team and they're so excited to bring another person onboard!
https://lnkd.in/grKRjWr7

Euro

Google Cloud CDN

Google Cloud Global Multi-Region

German Server Location

Co-Founder and CEO

David Younger

Co-Founder & CTO

Randolph Lopez

VP of Data Science

Ryan Emerson

Director of Machine Learning Research

Adrian Lange

Finance and Administration

Liz Fulton

Senior Director of Finance & Operations

Senior Director Biologics

Ryan Swanson

Office Manager

Debra Tonemah

Senior Laboratory and Facilities Manager

Ken Bannink

Technical Operations Manager

Samer Halabiya

Takeru Furuya

Matthew McIlwain

Ben Askew

Co-founder and CTO

Biotechnology Companies With More Than 100 Employees

West Coast Startups Founded in 2017

United States Early Stage Companies (Top 10K)

West Coast Early Stage Companies With Less Than $10M in Revenue

A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics.

A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Grant - A-Alpha Bio

Series A - A-Alpha Bio

Seed Round - A-Alpha Bio

Computer and Software Services and Scientific Services

Seattle

Washington

United States

North America

A-Alpha Bio Awarded Additional $14.5M from the Department of Defense to Accelerate Antibody Discovery and ...

A-Alpha Bio lands more DOD funding to expand work on biothreats

A-Alpha Bio lands $14.5M from Department of Defense to prep for future biological threats

Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation

A platform for quantitative, multiplexed characterization of protein-protein interactions using synthetic biology.

A machine learning model trained on protein interaction data to predict binding from protein sequences.

A service for discovering and engineering protein therapeutics with optimal binding properties.

A service for identifying weakly binding protein pairs that can be enhanced by small molecules.

Ukraine

Europe

Asimov is a synthetic biology platform focusing on protein interaction data analysis for therapeutic discovery.

Asimov

Arbor Biosciences is a company specializing in synthetic biology and protein interaction data analysis for therapeutic purposes.

Arbor Biosciences

Twist Bioscience is a synthetic biology company that focuses on DNA synthesis and protein interaction data analysis for various applications.

Twist Bioscience

ExonBIO is a biotechnology company that utilizes computational tools and yeast experiments to identify therapeutic proteins.

ExonBIO

DiscoveRx Corp is a provider of cell-based tools for protein interaction data analysis and high-throughput measurements.

DiscoveRx Corp

TetraGenetics Inc is a biotechnology company specializing in high-throughput measurements of protein interactions and therapeutic protein identification.

TetraGenetics Inc

A-Alpha Bio leverages synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. Their mission is to improve human health by unlocking the potential of protein-protein interactions. They generate high-resolution data to discover and optimize rare and effective antibodies, identify compatible protein pairs for molecular glues, and fuel machine-learning models to accelerate the discovery and optimization of high-impact drugs.

news impact assignment basic	general	Mar 2, 2024 12:35 AM	f94dc4d9
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 2, 2024 12:35 AM	2f2eb526
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	bf0a551a
crunchbase profile	general	Nov 25, 2024 9:46 AM	3c6fe559
li profile	general	Mar 2, 2024 12:35 AM	23f8f71e
translate crunchbase fundingrounds	general	Nov 25, 2024 1:53 PM	9c6ca92f
peers	general
news basic	general	Mar 2, 2024 12:35 AM	726bd55d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AALPHABIO

A-Alpha Bio